Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received
accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease …

Background Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …

Background Alzheimer's disease is a progressive, irreversible, and fatal disease for which
accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is …

Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in
the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi®) and
aducanumab (Aduhelm®)—have been approved in the USA for the treatment of Alzheimer's …

Vascular cognitive impairment and dementia (VCID) is commonly caused by vascular
injuries in cerebral large and small vessels and is a key driver of age-related cognitive …

Importance The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that …